Earendil Labs just raised $787M for AI-driven biologics. The largest AI biotech round of 2026 so far.

TL;DR

A company you’ve most likely never heard of, Earendil Labs, just raised $787M for AI-driven biologics — the largest AI biotech financing round of the year so far. Sanofi’s trajectory tells the real story: licensing partner (April 2025, $125M upfront, up to $1.72B in milestones) → strategic collaborator (January 2026, $160M upfront, up to $2.56B) → equity investor (March 2026, $787M round). Partner to repeat customer to investor in under twelve months. The investor list — DST Global, Hillhouse, Pfizer’s Dimension Capital — is global institutional money, not niche capital. Delaware incorporation paired with Beijing-based operations (Helixon Therapeutics) is the emerging architecture for Chinese AI biotech going global. The funding gap between China-origin platforms and Western counterparts is widening fast. If Chinese AI biotech isn’t on your radar yet, it should be.

A company youve most likely never heard of, Earendil Labs, just raised $787M for AI-driven biologics. The largest AI biotech financing round so far this year.

But it’s worth looking below the headline and see how Sanofi is involved in all this, and what it means for geopolitics.

In April 2025, Sanofi signed a licensing deal with Earendil for two bispecific antibodies. $125M upfront, up to $1.72B in milestones. A bet on the platform. In January 2026, Sanofi came back for a broader strategic collaboration. $160M upfront, up to $2.56B in milestones. A bet on the company. In March 2026, Sanofi invested in the $787M round. Now they’re a shareholder.

Partner to repeat customer to investor in under twelve months. That trajectory tells you more about the platform than any press release can.

Earendil’s AI-native engine has generated more than 40 programs to date. Its lead candidate, an anti-TL1A antibody, is Phase II-ready. Multiple IND submissions are planned for 2026 and 2027. For a company most people outside BD circles have never heard of, that’s a serious pipeline for its stage.

The investor list reinforces the signal. DST Global. Hillhouse Investment and Pfizer’s joint Biotech Development Fund Dimension Capital. This is not niche capital. This is global institutional money flowing into Chinese-origin AI biologics at scale.

To make the story even more interesting, Earendil Labs is incorporated in Delaware. Its affiliate, Helixon Therapeutics, operates out of Beijing. This is the emerging architecture for Chinese AI biotech going global: US legal entity for partnerships and IP protection, Chinese operations for the platform and the science.

It works. It is working. Sanofi, Pfizer (through Hillhouse), and DST are clearly comfortable with the structure.

But it also sits in an unresolved space. The BIOSECURE Act is still winding through Congress. US-China tensions over biotech IP and data flows are not getting simpler. And the question of how long this dual-structure model remains viable is one that no single financing round can answer.

What is clear: the AI biologics funding gap between China-origin platforms and their Western counterparts is widening fast. Earendil, XtalPi Inc., CSPC Pharmaceutical Group, Syneron Bio. The deal sizes keep growing. Western pharma keeps writing the checks.

If Chinese AI biotech isn’t on your radar yet, it should be. The capital flows are getting too large to treat as a niche story.

Key takeaways

• Earendil Labs closed a $787M round, the largest AI biotech financing of 2026 so far, backed by DST Global, Hillhouse, and Pfizer’s Dimension Capital.
• Sanofi’s arc — licensing partner → strategic collaborator → equity investor in under twelve months — is a stronger signal than the headline number.
• Earendil’s pipeline includes 40+ programs and a Phase II-ready anti-TL1A antibody, with multiple INDs planned for 2026 and 2027.
• Delaware incorporation paired with Beijing operations (Helixon Therapeutics) is the emerging architecture for Chinese AI biotech going global: US legal entity for partnerships and IP, Chinese ops for platform and science.
• The structure works for now. The BIOSECURE Act and US-China tensions over biotech IP and data flows leave its long-term viability genuinely open.
• The funding gap between China-origin AI biologics platforms (Earendil, XtalPi, CSPC, Syneron Bio) and Western counterparts is widening fast.
• Western pharma keeps writing the checks. The capital flows are too large to treat as a niche story.